Home » Stocks » OPGN

OpGen, Inc. (OPGN)

Stock Price: $2.25 USD -0.02 (-0.88%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $2.28 +0.03 (1.33%) May 12, 6:30 PM
Market Cap 90.31M
Revenue (ttm) 4.21M
Net Income (ttm) -26.21M
Shares Out 15.80M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.25
Previous Close $2.27
Change ($) -0.02
Change (%) -0.88%
Day's Open 2.27
Day's Range 2.23 - 2.42
Day's Volume 814,618
52-Week Range 1.63 - 4.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2...

1 week ago - GlobeNewsWire

GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-...

3 weeks ago - GlobeNewsWire

Experts presented the results of their Unyvero studies and demonstrated:

1 month ago - GlobeNewsWire

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -20.69% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -6.90% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Conference call to be held at 4:30 p.m. Eastern Time today

1 month ago - GlobeNewsWire

OpGen (NASDAQ:OPGN) unveils its next round of earnings this Thursday, March 25. Get prepared with Benzinga's ultimate preview for OpGen's Q4 earnings.

1 month ago - Benzinga

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter ...

2 months ago - GlobeNewsWire

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Other stocks mentioned: IMVT, ANCN
2 months ago - Benzinga

OpGen (OPGN) stock is flying high on Monday following results from a study published in a peer-reviewed publication concerning coronavirus. The post OPGN Stock: 9 Things for OpGen Investors to Know as S...

2 months ago - InvestorPlace

Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients

2 months ago - GlobeNewsWire

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat in...

2 months ago - GlobeNewsWire

Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data

2 months ago - GlobeNewsWire

GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...

3 months ago - GlobeNewsWire

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinf...

4 months ago - GlobeNewsWire

Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth  

5 months ago - GlobeNewsWire

Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing

5 months ago - GlobeNewsWire

GAITHERSBURG, Md., Nov. 24, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...

5 months ago - GlobeNewsWire

Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens

6 months ago - GlobeNewsWire

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Conference call to be held at 4:30 p.m. Eastern Time today

6 months ago - GlobeNewsWire

GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 20...

6 months ago - GlobeNewsWire

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinf...

6 months ago - GlobeNewsWire

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...

6 months ago - GlobeNewsWire

GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...

6 months ago - GlobeNewsWire

Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions

7 months ago - GlobeNewsWire

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Sept. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bio...

7 months ago - GlobeNewsWire

GAITHERSBURG, Md., Sept. 18, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due ...

7 months ago - GlobeNewsWire

Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

7 months ago - GlobeNewsWire

Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic Affairs

8 months ago - GlobeNewsWire

GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 02, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bi...

8 months ago - GlobeNewsWire

OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its subsidiary obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB detection of SARS-...

8 months ago - Benzinga

Shares of Maryland-based OpGen Inc. OPGN, -0.96% rocketed 43% in active premarket trading Thursday, after the molecular diagnostics company said its Germany-based Curetis GmbH subsidiary obtained the CE...

8 months ago - Market Watch

- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour

8 months ago - GlobeNewsWire

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of OpGen (NASDAQ:OPGN) rose 4.98% in after-market trading after the company reported Q2 results.

9 months ago - Benzinga

Conference call to be held at 4:30 p.m. Eastern Time today

9 months ago - GlobeNewsWire

OpGen (NASDAQ: OPGN) will be releasing its next round of earnings this Wednesday, August 12.

9 months ago - Benzinga

Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database

9 months ago - GlobeNewsWire

GAITHERSBURG, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and promotion, on ...

9 months ago - GlobeNewsWire

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...

9 months ago - GlobeNewsWire

GAITHERSBURG, Md., July 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN)(“OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infe...

9 months ago - GlobeNewsWire

Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products Strategic partnership will focus on commercializing CEL...

9 months ago - GlobeNewsWire

-  European Investment Bank (EIB) and OpGen, Curetis GmbH and Ares Genetics GmbH enter into Amendment to the EIB Financing Agreement

10 months ago - GlobeNewsWire

If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.

Other stocks mentioned: AGEN, AMRS, INSE, RTIX
10 months ago - Forbes

OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.

11 months ago - Benzinga

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, June 09, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioi...

11 months ago - GlobeNewsWire

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infec...

1 year ago - GlobeNewsWire

About OPGN

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification o... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 5, 2015
CEO
Oliver Schacht
Employees
94
Stock Exchange
NASDAQ
Ticker Symbol
OPGN
Full Company Profile

Financial Performance

In 2020, OpGen, Inc.'s revenue was $4.21 million, an increase of 20.46% compared to the previous year's $3.50 million. Losses were -$26.21 million, 110.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for OpGen, Inc. stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 144.44% from the latest price.

Price Target
$5.50
(144.44% upside)
Analyst Consensus: Buy